Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temziva versus Actemra in active rheumatoid arthritis
IRCT20150303021315N9Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by AryoGen Biopharma. Primary endpoint: ACR20 response at week 24. Started Nov 2022; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on IRCT20150303021315N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N9.